High-stakes clinical trials define the 2026 landscape for Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms seek to revolutionize patient care while navigating the complex path toward regulatory approval.
Dyne targets rare neuromuscular conditions with a proprietary delivery platform, while Viking focuses on the massive metabolic and endocrine markets. Comparing these two helps you understand whether to bet on specialized orphan diseases or high-demand weight-loss therapies. Both companies are clinical-stage, meaning they are still testing products and do not yet have recurring sales.
The case for Dyne Therapeutics
Dyne focuses on the FORCE platform to deliver targeted therapies for neuromuscular diseases like Duchenne muscular dystrophy and Pompe disease. By utilizing its proprietary platform, the company aims to overcome limitations of current treatments by improving the delivery of genetic medicine to muscle tissue. It currently generates no commercial revenue and depends on a critical loan agreement with Hercules Capital for its operational funding. The company also relies on various third-party organizations to manufacture its drug components and conduct its clinical trials.
During FY 2025, the company reported revenue of $0.0. The business recorded a net loss of nearly $446.2 million for the year. This reflects a substantial increase in losses from the $317.4 million loss seen in the previous fiscal year. Management has prioritized advancing its lead product candidates, which requires significant capital for late-stage studies. These mounting costs are typical for firms in the biotech sector as they invest heavily in research and development.
As of its December 2025 balance sheet, the debt-to-equity ratio is 0.19x. This metric compares total debt to shareholder equity to see how much a company relies on lenders. The current ratio, which measures the ability to cover short-term debts with current assets, is approximately 22.3x. A ratio above 1.0 generally suggests a healthy cushion for meeting near-term financial obligations. Free cash flow, which is cash from operations minus capital spending, was roughly negative $405.1 million for FY 2025.
The case for Viking Therapeutics
Viking Therapeutics develops novel therapies for metabolic and endocrine disorders, with a primary focus on its weight-loss candidate VK2735. It relies on a master license agreement with Ligand Pharmaceuticals for the rights to its most important drug assets. Beyond weight loss, the company is also targeting rare diseases like X-linked adrenoleukodystrophy to diversify its clinical pipeline. The company also maintains a significant agreement with Corden Pharma to handle the production of its active pharmaceutical ingredients.
